M2 TAMs, characterized by a CD68+/CD163+ phenotype, release cytokines that deplete tumor-infiltrating lymphocytes (TILs), inactive killer T cells and facilitate tumor immune evasion (28). This evidence concerns the gene CD163 and neoplasm.